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Background:  Reduction of mitral valve regurgitation using the transcatheter MitraClipTM system has been shown to be safe, feasible and effective 
compared to surgical mitral valve repair. Heart failure patients with reduced ejection fraction often suffer from severe mitral valve regurgitation 
which contributes to repeated cardiac decompensation and dyspnea. However, surgical mitral valve repair is considered to be a high-risk procedure 
in these patients. Thus, the aim of our study was to evaluate MitraClipTM-mediated mitral valve repair in end-stage heart failure patients with severe 
mitral regurgitation.
Methods:  Since 2009, 51 patients were treated with the MitraClipTM-system. 25 of these patients had end-stage heart failure (68±8.7 years; 80% 
male) and severe symptomatic functional (n=15; 60%) or degenerative (n=10; 40%) mitral regurgitation (MR ≥ grade 3+). Mean Society of Thoracic 
Surgeons (STS) risk score of perioperative mortality was 19.1±11%. Cardiac function was severely reduced in these patients (mean left ventricular 
ejection fraction: 22±6%; mean cardiac index: 1.9±0.4 l/min/m2; mean systolic pulmonary artery pressure: 56±9 mmHg; mean brain natriuretic 
peptide: 5325±4636 ng/l).
Results:  MitraClipTM implantation was successful in 23 patients (92%). Most patients were treated with a single clip (n=14; 56%), 9 patients 
(36%) received two clips. The average reduction of mitral regurgitation was from grade 3.2±0.4 before mitral valve repair to grade 1.7±0.7 one 
month after MitraClipTM implantation (P<0.05). Mitral valve repair translated in reduced New York Heart Association (NYHA) functional class by 
one grade (mean NYHA functional class before MitraClipTM implantation: 3.4±0.4 vs. 2.4±0.7 one month after discharge; P<0.05). There was no 
procedure-related in-hospital mortality.
Conclusions:  Mitral valve repair using the MitraClipTM system in end-stage heart failure patients is feasible, safe and results in significant 
clinical benefit. Transcatheter mitral valve repair should be considered as first-line therapeutic option in heart failure patients with severe mitral 
regurgitation, high operative risk, and suitable anatomy of mitral valve leaflets.
